ClinicalTrials.gg
WithdrawnNCT02926495Updated Feb 23, 2017

Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.

An interventional study of eCoin System in Resistant Hypertension, sponsored by Valencia Technologies Corporation. Withdrawn. Open to participants aged 30 Years to 74 Years. Per ClinicalTrials.gov, last updated 2017-02-23.

Sponsored by Valencia Technologies Corporation · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
The study was stopped before start because the project was not fully-funded.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
30 Years to 74 Years
Sex
All
01

Study summary

Hypertension is a serious public health issue, affecting approximately 30% of adults. Hypertension greatly contributes to the risk for heart disease and stroke, both among the top three leading causes of death in the Americas, Europe, and Asia. While most treated individuals with hypertension are controlled on medication, diet and exercise, an estimated 12% are resistant to conventional medical intervention. Alternative effective treatments are still needed for this hypertensive patient population to mitigate the risk and incidence of mortality and morbidity.

This original Investigational Device Application is for a study intended to confirm the safety and efficacy of bilateral subcutaneous median nerve stimulation using the eCoin system to treat resistant hypertension. The eCoin device delivers electrical stimulation pulses to the median nerve from a small coin sized device placed under the skin of the distal anterior forearm. The implant delivers a weekly 30 minute treatment based on previous studies showing a long lasting and cumulative effect. The safety and efficacy of eCoin therapy has previously been demonstrated in a multinational, randomized, double-blind, sham-controlled study in New Zealand, Taiwan and Canada.

This trial is a multi-center, prospective, double-blind, 1:1 randomized sham-controlled study of the safety and effectiveness of eCoin median nerve neuromodulation in subjects with drug-treatment resistant hypertension. The eCoin neuromodulation device will be implanted subcutaneously in the right and left forearms of patients with uncontrolled hypertension despite treatment with 3 or more antihypertensive agents. After a 4 week implant healing period, subjects will be 1:1 randomized into either a treatment or control group. One half of the subjects have their devices activated (treatment) and the other half undergo a sham activation (control) to maintain participant blinding to their treatment allocation. During the six months post-randomization, the eCoin is ON in the treatment group and OFF in the control group.

02

Conditions studied

  • Resistant Hypertension

Browse trials for

03

In context

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Lead sponsor

Valencia Technologies Corporation is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individual is ≥30 and \<75 years of age at the time of randomization.
  • Individual is receiving a stable medication regimen including maximally tolerated doses of 3 or more anti-hypertensive medications of different classes, of which one must be a diuretic (with no changes for a minimum of 4 weeks prior to screening) that is expected to be maintained without changes for at least 6 months post randomization.
  • Individual has an office systolic BP ≥140 mmHg and ≤180 mmHg and diastolic BP ≥80 mmHg and ≤110 mmHg measured at an initial screening visit and a confirmatory baseline visit.
  • Individual has a 24 hour ambulatory systolic BP of ≥135 mmHg and ≤175 mmHg at baseline.

Exclusion criteria

Exclusion Criteria:

  • Individual in whom medications are expected to change in the next 9 months (6 months post randomization).
  • Individual does not agree to have all study procedures performed, and is not competent and willing to provide written, to participate in this clinical study.
  • Individual has type 1 diabetes mellitus or type 2 diabetes mellitus with an ≥ 9%.
  • Individual has experienced, within one year of the screening visit, a myocardial infarction, hospitalized unstable angina pectoris, hospitalized heart failure, or a cerebrovascular accident.
  • Individual has a scheduled or planned surgery, cardiovascular intervention, or dialysis in the next six months.
  • Individual has hemodynamically significant valvular heart disease for which reduction of BP would be considered hazardous.
  • Individual has any serious medical condition with a prognosis of \<2 years.
  • Individual has significant anemia ( \<100g/L), thrombocytopenia ( \<100x10(9) /L) or a severe bleeding disorder eg. hemophilia.
  • Individual has known secondary hypertension including primary aldosteronism (other than associated with obstructive sleep apnea).
  • Individual has pulmonary hypertension.
  • Individual requires chronic oxygen support or mechanical ventilation (e.g., tracheostomy, CPAP, BiPAP) other than nocturnal respiratory support for sleep apnea.
  • Individual is pregnant, nursing or planning to become pregnant.
  • Individual has known or suspected history of medication non-compliance.
  • Individual has known unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.
  • Individual has undergone renal denervation or baroreflex activation therapy.
  • Individual has an estimated (eGFR) \<30 mL/min/1.73m2.
  • Individual has another implantable stimulation device including a cardiac pacemaker, ICD, spinal cord stimulator, brain stimulator, vagus nerve stimulator, peripheral nerve stimulator, or cochlear implant.
  • Individual is scheduled to have an MRI.
  • Individual is currently enrolled in another drug or device trial that has not reached its primary endpoint.
  • Individual is working nights or is on a rotating work schedule.
  • Individual has an arm circumference too large or small to allow accurate blood pressure measurement with available devices.
  • Individual has a history of carpal tunnel syndrome/wrist surgery or other pre-existing compression or non-compression neuropathy in the forearm, wrist or hands that is incompatible with device placement.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Treatment (ON)

    Device: eCoin System

  • Sham comparator
    Control (OFF)

    Device: eCoin System

Interventions

  • DeviceeCoin System

    Median nerve neurostimulator.

06

What researchers measure

Primary outcomes

  1. Difference in Change in 24-hr SBP Between Groups at 6 Months

    The difference in 24-hour ambulatory systolic blood pressure change from baseline to 6 months post-randomization between the eCoin neuromodulation ON (Treatment) and eCoin neuromodulation OFF (Control) groups.

    Time frame: From baseline to 6 months post-randomization.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2016; primary completion for May 2018, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2016
First posted
Oct 6, 2016
StartEst.
Nov 2016
Primary completionEst.
May 2018
CompletionEst.
Dec 2018
Last update
Feb 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02926495
Lead sponsor
Valencia Technologies Corporation
Responsible party
Sponsor
First posted
Oct 6, 2016
Start date
Nov 2016 (estimated)
Primary completion
May 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Feb 23, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion